Kintara Therapeutics has initiated a process to explore and review a range of strategic alternatives focused on maximizing stockholder value. Kintara has engaged Ladenburg Thalmann & Co. to act as financial advisor for this process.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KTRA:
- Kintara Therapeutics granted extension by Nasdaq to regain compliance
- Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
- Kintara Therapeutics downgraded to Hold from Buy at Maxim
- Kintara Therapeutics suspends development of VAL-083 after topline results
